Suven Life Sciences Limited Statistics
Want to see IN:SUVEN full AI Analyst Report?
Suven Life Sciences Limited (SUVEN) Stock Statistics & Valuation Metrics
Total Valuation
Suven Life Sciences Limited has a market cap or net worth of INR 78.67B. The enterprise value is INR 87.11B.
- Market Cap
- INR 78.67B
- Enterprise Value
- INR 87.11B
Share Statistics
Suven Life Sciences Limited has 282,562,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 282,562,680
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Suven Life Sciences Limited’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -47.56%.
- Return on Equity (ROE)
- -0.47
- Return on Assets (ROA)
- -0.44
- Return on Invested Capital (ROIC)
- -47.56%
- Return on Capital Employed (ROCE)
- -0.49
- Revenue Per Employee
- 504.59K
- Profits Per Employee
- -19.60M
- Employee Count
- 141
- Asset Turnover
- 0.01
- Inventory Turnover
- 480.81
Valuation Ratios
The current PE Ratio of Suven Life Sciences Limited is -23.74. Suven Life Sciences Limited’s PEG ratio is 0.81.
- PE Ratio
- -23.74
- PS Ratio
- 694.65
- PB Ratio
- 17.25
- Price to FCF
- -59.86
- Price to Operating Cash Flow
- -75.68
- PEG Ratio
- 0.81
Income Statement
In the last 12 months, Suven Life Sciences Limited had revenue of 71.15M and earned -2.76B in profits. Earnings per share was -12.13.
- Revenue
- 71.15M
- Gross Profit
- -419.28M
- Operating Income
- -2.90B
- Pretax Income
- -2.76B
- Net Income
- -2.76B
- EBITDA
- -2.71B
- Earnings Per Share (EPS)
- -12.13
Cash Flow
In the last 12 months, operating cash flow was -1.03B and capital expenditures -21.37M, giving a free cash flow of -1.06B billion.
- Operating Cash Flow
- -1.03B
- Free Cash Flow
- -1.06B
- Free Cash Flow per Share
- -3.74
Dividends & Yields
Suven Life Sciences Limited pays an annual dividend of INR 1.38, resulting in a dividend yield of ―
- Dividend Per Share
- INR 1.38
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.67%
- Earnings Yield
- -3.73%
Stock Price Statistics
- Beta
- 1.50
- 52-Week Price Change
- 52.26%
- 50-Day Moving Average
- 304.27
- 200-Day Moving Average
- 258.70
- Relative Strength Index (RSI)
- 47.03
- Average Volume (3m)
- 48.24K
Important Dates
Suven Life Sciences Limited upcoming earnings date is Feb 14, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 14, 2027
- Ex-Dividend Date
- Feb 14, 2019
Financial Position
Suven Life Sciences Limited as a current ratio of 17.69, with Debt / Equity ratio of 2.82%
- Current Ratio
- 17.69
- Quick Ratio
- 17.69
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.19
- Interest Coverage Ratio
- -1838.51
Taxes
In the past 12 months, Suven Life Sciences Limited has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Suven Life Sciences Limited EV to EBITDA ratio is -21.71, with an EV/FCF ratio of -59.79.
- EV to Sales
- 693.76
- EV to EBITDA
- -21.71
- EV to Free Cash Flow
- -59.79
- EV to Operating Cash Flow
- -61.02
Balance Sheet
Suven Life Sciences Limited has INR 5.18B in cash and marketable securities with INR 166.94M in debt, giving a net cash position of INR 5.01B billion.
- Cash & Marketable Securities
- INR 5.18B
- Total Debt
- INR 166.94M
- Net Cash
- INR 5.01B
- Net Cash Per Share
- INR 17.75
- Tangible Book Value Per Share
- INR 26.19
Margins
Gross margin is -331.69%, with operating margin of -3455.63%, and net profit margin of -3205.79%.
- Gross Margin
- -331.69%
- Operating Margin
- -3455.63%
- Pretax Margin
- -3205.79%
- Net Profit Margin
- -3205.79%
- EBITDA Margin
- -3195.30%
- EBIT Margin
- -3276.53%
Analyst Forecast
The average price target for Suven Life Sciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 55.10%
- EPS Growth Forecast
- -50.35%
Scores
- Smart Score
- ―
- AI Score
- 43

